Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088517 · ClinicalTrials.gov registry record · Phase 1
Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112
A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00088517 is a Phase 1 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 10 participants.
The verdict
NCT00088517, a Phase 1 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will investigate the use of \[11C\]NNC-112 in positron emission tomography (PET) scanning. PET is a technique that uses radioactive isotopes called tracers to provide images of the brain. Injected into the body, the isotopes lose their "radioactive strength" over time, sending out rays that can be picked up and "seen" by special detectors connected to a computer. The computer then makes a picture of the brain. This study will examine the distribution in the body of a new tracer called \[11C\]NNC-112. Healthy normal volunteers between 18 and 70 years of age may be eligible for this study. Candidates are screened with a physical examination and blood and urine tests, including a urine drug screen. Women up to age 55 also have a pregnancy test. Participants have a PET scan using the \[11C\]NNC-112 tracer. For this procedure, a catheter (small plastic tube) is placed into a vein in the subject's arm for injecting the tracer. Then, the subject lies on the scanner bed. After a preliminary "transmission scan," the tracer is injected, and PET scans are taken from the head to the upper thigh over a period of about 2 hours to show the distribution of radioactivity in the body. Blood pressure, breathing rate, and heart rate are checked before and after injection of the tracer, and blood and urine samples are collected after the PET scan.
Interventions
- DRUG [11C]NNC-112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088517
The ClinicalTrials.gov registry entry for NCT00088517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]NNC-112 is the first listed.
NCT00088517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088517 about?
NCT00088517 is a clinical study titled "Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112". This study will investigate the use of \[11C\]NNC-112 in positron emission tomography (PET) scanning. PET is a technique that uses radioactive isotopes called tracers to provide images of the brain. Injected into the body, the isotopes lose their "radioactive strength" over time, sending out rays th...
What is the current status of trial NCT00088517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2004-07. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00088517?
The interventions under investigation include: [11C]NNC-112 (DRUG).
Who is sponsoring clinical trial NCT00088517?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.